Median Technologies : Changes in the rights attaching to the classes of shares or securities

Press release - For immediate release

May 10, 2024 - 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the

capital as of April 30th, 2024

Pursuant to article L-223-8 II of the French "code de Commerce" and

223-16 of the AMF's General Regulations.

Sophia Antipolis, France

Total number of shares	18,418,233
Number of real voting rights*	18,346,685
(excluding treasury shares**)
Theoretical number of voting rights*	18,298,337
(including treasury shares**)

(*) Class E preference shares are non-voting

1. pursuant to article 223-11 of the AMF's General Regulations

About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN:

FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).

For more information: www.mediantechnologies.com

Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol	Ghislaine Gasparetto
Head of Corporate Marketing & Financial	[phone]	[phone]
Communications	[e-mail]	[e-mail]
[phone]
[e-mail]

1 | P a g e